Purchase this article with an account.
S. J. Kang, H. Yang, H. E. Grossniklaus; Subconjunctival Doxorubicin Does Not Reduce Tumor Burden in Transgenic Murine Retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2068.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of subconjunctival doxorubicin in the treatment of transgenic murine retinoblastoma
Poly(lactide-co-glycolide) (PLGA) nanoparticles loaded with doxorubicin were prepared. LHβ-Tag mice were randomly assigned into 3 groups, and treated at 10 weeks of age. Each mouse received a single subconjunctival injection in one eye, and the opposite eye was left untreated as a control. Group 1 (nanoparticle group, 10 mice) received nanoparticle doxorubicin (2 mg/ml final drug concentration). Group 2 (conventional group, 10 mice) received same concentration of conventional doxorubicin, and group 3 (PBS group, 5 mice) received phosphate-buffered saline (PBS). Mice were killed on day 22 after treatment. Eyes were serially sectioned, and retinal tumor burden was quantified by histopathologic analysis with image analysis by Image J. .
Mean tumor burden in the nanoparticle group did not show significant change compared to the untreated eyes in the same mice (P=0.96), conventional doxorubicin-treated group (P=0.67), and PBS treated group (P=0.88). A single subconjunctival injection of conventional doxorubicin did not show significant decrease in tumor burden compared to the PBS treated group (P=0.37) Histologic evidence of toxicity such as subretinal hemorrhage, choroid atrophy, and extension of the tumor to the choroid was observed in the conventional doxorubicin group, but not in the nanoparticle group.
A single injection of subconjunctival conventional or nanoparticle doxorubicin does not show significant decrease in tumor burden in the treatment of transgenic murine retinoblastoma.
This PDF is available to Subscribers Only